قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Nearly 60% of eligible patients never offered statin treatment

Nearly 60% of eligible patients never offered statin treatment



Statin therapy was not offered more than half of the patients eligible for the therapy, which could potentially be associated with adverse reaction concerns, according to a study published in Journal of the American Heart Association .

"We must focus our efforts on improving how doctors identify patients who need to be on statin and how they present information to patients to ensure that no one lacks the ability to improve their heart's health" Corey K Bradley, MD, researcher at the Duke Clinical Research Institute, said in a press release.

Researchers analyzed data from 5,693 patients from the PALM registry who would have been recommended statin therapy based on the 201

3 American College of Cardiology / American Heart Association Guideline. Registry patients completed studies to obtain information on previous statin experience, current statin utilization, and conviction of their risk of atherosclerotic CVD, confidence in their healthcare provider, and statin safety and efficacy. Lipid panels and other clinical properties were also evaluated.

Patients were then categorized by statin use: currently under treatment (n = 4,182, medieval, 68 years, 61% males), former discontinued statin users (n = 464, mean age, 68 years, 43% men) offered therapy but dropped (n = 153, medieval, 67 years, 42% men) and never offered treatment (n = 894, medieval, 68 years, 49% men)

Statin therapy was not offered more than half According to a study published in the patients eligible for the therapy may be potentially associated with concern for side effects.

Source: Adobe Stock

Of the 1,511 non-statins, 59.2% said they were never offered them. Patients most likely to report were never offered a statin, included black adults (RR = 1.48, 95% CI, 1.2-1.8), women (RR = 1.22, 95% CI, 1 , 06-1.41) and those without insurance (RR = 1.38; 95% CI, 1.06-1.81).

The most common reason for rejecting or discontinuing statin therapy was the fear of side effects (36.8%). Compared to patients currently taking statins, they were less likely to believe that the therapy was effective (86.3% of current users, 67.4% of those who fell and 69.1% of them, ceased) or safely (70.4% of current users, 36.9% of those who fell and 37.4% of those who ceased). The willingness to take statin was high in patients who discontinued treatment (59.7%) and those who were never offered statin therapy (67.7%).

"Perceptions of statin security rather than perceptions of [atherosclerotic] CVD risk or statin benefit appear to be driving statin utilization among those who reject or discontinue treatment," Bradley and colleagues wrote. – Darlene Dobkowski

Disclosure s : The PALM register was funded by Sanofi and Regeneron Pharmaceuticals. Bradley does not report relevant financial information. Please see the study for all other authors' relevant financial information.


Source link